Indivior PLC stock (GB00BYZ0C031): U.S.-listed shares trade steadily as investors watch litigation and growth outlook

Indivior PLC shares on Nasdaq continue to trade in a tight range as investors weigh the specialty addiction-treatment group’s U.S. class action, growth in key products and broader sector sentiment.

Indivior PLC shares on the Nasdaq, where the company is listed under the ticker INDV, have been trading relatively steadily in recent sessions as investors balance ongoing U.S. securities litigation with expectations for continued growth in its addiction-treatment franchise, according to recent market data as of late May 2026 from Morningstar and other exchange sources.

The specialty pharmaceuticals group, headquartered in the United Kingdom and focused on treatments for opioid-use disorder, remains actively traded in the United States after its move to a primary listing on Nasdaq, with a market capitalization of about USD 3.98 billion as of June 2026, according to Companies Market Cap.

Recent stock commentary highlights that a class-action lawsuit is pending in the United States, with Robbins LLP reminding Indivior PLC stockholders in May 2026 about lead-plaintiff deadlines linked to alleged securities-law violations, as noted in a Robbins LLP announcement summarized by Invezz and other news aggregators.

While this legal overhang is on investors’ radar, earnings-related commentary emphasizes that Indivior has shown strong fundamental momentum, with Zacks reporting in late May 2026 that Indivior-related earnings have beaten consensus estimates in each of the last four quarters, with an average surprise above 60 percent for the tracked period.

Price-target data compiled by Zacks and other analyst aggregators suggest that, as of late May 2026, the average 12-month price target for Indivior PLC American Depositary Shares is around USD 19, based on three short-term analyst forecasts in the U.S. market, with a range from USD 13 to USD 22.

On its home market dimension, Indivior’s operational and regulatory center of gravity remains the United Kingdom, but the group has increasingly oriented its capital-market presence toward the United States via the Nasdaq listing, reflecting the fact that its core commercial footprint and the bulk of revenues are generated in the U.S. addiction-treatment market.

In Germany, Indivior is also available via off-exchange venues such as Tradegate, where the stock can be traded in euros by retail investors who wish to gain exposure to the U.S.-listed shares during extended trading hours; indicative quotes in late May 2026 showed the euro price closely tracking the U.S. dollar line adjusted for exchange rates.

As of: 06/03/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Indivior
• Sector/industry: Specialty pharmaceuticals, addiction treatment
• Headquarters/country: Slough, United Kingdom
• Core markets: United States, United Kingdom, selected international markets
• Key revenue drivers: Medications for opioid-use disorder and related psychiatric conditions, primarily in the U.S. market
• Home exchange/listing venue: Nasdaq (INDV)
• Trading currency: USD

Indivior PLC: core business model

Indivior generates most of its revenue from branded therapies targeting opioid-use disorder and other addiction-related conditions, with the U.S. healthcare system providing the dominant share of its sales.

Indivior PLC in peer comparison

Viewed against other addiction- and psychiatry-focused drug makers, Indivior is often compared to companies such as Alkermes and Opiant-related businesses, which also develop or market treatments aimed at substance-use disorders and central nervous system conditions in the United States.

Alkermes, for example, derives a substantial portion of its revenues from long-acting injectable therapies for psychiatric and addiction indications, and had a market capitalization in the mid-single-digit billion U.S. dollar range in early 2026, positioning it broadly in the same valuation bracket as Indivior on a headline basis.

Another relevant comparator is the broader specialty-pharmaceuticals cohort listed in the United States, encompassing mid-cap names with concentrated portfolios in high-need therapeutic niches, where valuation often reflects a balance between product-concentration risk, regulatory exposure and the durability of patent-protected cash flows.

Conclusion

For Indivior PLC, the current trading pattern on Nasdaq reflects a balance between confidence in its addiction-treatment franchise and caution around the pending U.S. class action and other legal matters. In peer comparison, the company sits within a group of mid-cap specialty pharma names where valuations hinge on the perceived durability of key products and the management of regulatory and litigation risk. How these factors evolve over the coming quarters will shape whether Indivior more closely tracks its peer group or diverges based on company-specific developments.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.